Literature DB >> 21637310

Therapy: Rituximab for refractory SLE--patients reach lasting remission with short-term regimen.

Emma Leah.   

Abstract

Entities:  

Year:  2011        PMID： 21637310     DOI： 10.1038/nrrheum.2011.56

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.

Authors:  Dario Roccatello; Savino Sciascia; Daniela Rossi; Mirella Alpa; Carla Naretto; Simone Baldovino; Elisa Menegatti; Rita La Grotta; Vittorio Modena
Journal:  Nephrol Dial Transplant       Date:  2011-03-08       Impact factor: 5.992
  1 in total
  3 in total

1.  Immunotherapy targets in pediatric cancer.

Authors:  Rimas J Orentas; Daniel W Lee; Crystal Mackall
Journal:  Front Oncol       Date:  2012-01-30       Impact factor: 6.244

2.  IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy.

Authors:  Giacomo Quattrocchio; Antonella Barreca; Andrea Demarchi; Laura Solfietti; Giulietta Beltrame; Roberta Fenoglio; Michela Ferro; Paola Mesiano; Stefano Murgia; Giulio Del Vecchio; Carlo Massara; Cristiana Rollino; Dario Roccatello
Journal:  Oncotarget       Date:  2018-04-20

3.  Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement.

Authors:  Giacomo Quattrocchio; Antonella Barreca; Andrea Demarchi; Roberta Fenoglio; Michela Ferro; Giulio Del Vecchio; Carlo Massara; Cristiana Rollino; Savino Sciascia; Dario Roccatello
Journal:  Immunol Res       Date:  2020-11-10       Impact factor: 2.829
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.